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BACKGROUND: Recently, stroke therapy is focused on reperfusion therapies for restoring cerebral blood flow (CBF) and minimizing the undesired effects 
of neuron ischemia. However, the thrombolytic therapy to 
restore CBF was restricted with narrow time window. On 
the other hands, not many patients can reach the treatment 
immediately after the onset of stroke. A wider time window 
therapy that might increase CBF would probably helpful. 
This study aims to investigate the CBF improvement after 
intra arterial heparin flushing (IAHF) therapy in chronic 
stroke patients. 
METHODS: A clinical trial was conducted with time 
sampling. We collected chronic ischemic stroke subjects 
(with stroke onset ≥30 days) within periods February-
September 2015. We investigated CBF before and after 
IAHF treatment in 75 chronic stroke patients. The difference 
before and after IAHF treatment in subgroup which is 
classified with infarct size and lesion area was tested. CBF 
was measured using MRI Quality Arterial Spin Labeling 
(qASL) with region of interest around infarct lesion.  
RESULTS: We found a significant CBF improvement 
(p<0.001) around infarct area after IAHF treatment with 
average 10.39mL/100g/min raised. CBF improvement was 
found in lacunar infarct (p<0.001) and non lacunar (p<0.001), 
also in infarct in cortical (p<0.05), subcortical(p<0.001) and 
both area (p<0.05).
CONCLUSION: IAHF is associated with increased CBF 
around infarct area and IAHF probably offers some benefit 
for chronic stroke.
KEYWORDS: IAHF, CBF, chronic stroke, ischemic, 
lacunar, non lacunar, cortical lesion, subcortical lesion
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Abstract
Introduction
Stroke is the second leading cause of adult mortality and 
long term disability. Globally, stroke is also known as 
production and economic burdens.(1,2) This has been 
provoking a lot of studies to find out a better understanding 
on stroke therapy in the last decades.(3,4) 
 Multiple clinical trials showed sudden decrease 
of cerebral blood flow (CBF) that can lead to a complex 
pathophysiology of ischemic cascade including 
excitotoxicity, inflammation, oxidative damage and ion 
imbalance, which lead to cerebral infarct CBF restoration 
either spontaneously or by reperfusion therapy, is needed 
in time to recover glial and neuron cells after ischemic 
injury. Recent studies are still focusing on how to improve 
CBF effectively.(5) The penumbra was classically defined 
as the hypoperfused tissue surrounding the ischemic core 
in which blood flow is too low to maintain electric activity 
but sufficient to preserve ion channels. New definition of 
penumbra defines that penumbra is peri-infarcted tissue 
which serves as boundary zone between dead and healthy 
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Methods
tissue. From a therapeutic point of view, the ischemic 
penumbra is a target for brain plasticity and neurorepair 
treatments.(6) 
 Thrombosis plays an important role in ischemic stroke 
pathogenesis. Many attempts had been done to find the most 
suitable thrombolytic therapy regiment to obtain higher 
cerebral perfusion after ischemia.(7,8, 9) So far only serine 
protease tissue-type plasminogen activator was approved 
by FDA as a thrombolytic agent for stroke treatment. 
Randomized controlled trials (RCT) data from European 
Cooperative Acute Stroke Study (ECASS) III and the Safe 
Implementation of Thrombolysis in Stroke International 
Stroke Treatment Registry (SITS-ISTR) showed that 
intravenous recombinant tissue plasminogen activator can 
effectively improve the outcome of patients with ischemic 
stroke  when  delivered  within  3-4.5 hours after stroke 
onset.(8,10) However, many patients with viable penumbra 
were not treated by reperfusion therapies.(6) In Gatot 
Soebroto Army Central Hospital, 57.33% ofstroke patients 
came in chronic phase (after 30 days). Thus, new therapeutic 
strategies with a wider window time will be very useful to 
reduce after ischemic morbidity in chronic phase.(10) 
 After recanalization treatment with recombinant 
tissue plasminogen activator, clot dissolution followed 
by a significant hyperemia within the ischemic region 
immediately occurs. However, this is followed by a post 
ischemic hypoperfusion, which can last for hours. This 
is described as the ‘no-reflow phenomenon’ and has been 
attributed to the narrowing of capillaries.(11) Capillary 
pericytes has an important role in the long-lasting blood flow 
decrease following ischemia. Pericytes constrict capillaries 
at the start of a stroke, and then stay in rigor (because no 
ATP is available to relax their contractile filaments), causing 
the capillaries to remain small for the passage of red blood 
cells. Suppression of oxidative and nitrosative stress 
prevents these pericytes constriction, restores the patency of 
capillaries, and improves tissue recovery.(12) This showed 
that the current treatment have limitation in window time 
and in inducing microvascular reperfusion.
 Digital subtraction angiography (DSA) which was 
modified with intra arterial heparin flushing (IAHF) in 
Gatot Soebroto Army Central Hospital showed a clinical 
improvement in chronic stroke patients empirically. In radio 
intervention procedure, heparin usually used as flushing 
solution for catheterization.(13) Heparin not only plays 
role as an anticoagulant but also plays role as a fibrinolytic. 
Heparin increases plasminogen conversion into plasmin by 
stimulating tissue plasminogen activator.(14) Heparin has 
potential in increasing thrombolysis by inhibiting thrombin 
activatable  fibrinolysis  inhibitor  (TAFI)  formation.(15) 
Thus,  heparin  is  commonly   used  to  treat   both  arterial 
and venous  thrombosis  because   of  its   safety-proven 
reason.(3,16,17) Intravascular studies showed that heparin 
therapy can reduce the clot size (18), suggested by its 
potency in brain reperfusion after ischemic. The potential of 
heparin a s  antioxidant is  well  known, so that it  is  used 
in   hemodialysis   to  suppress  oxidative  stress  during 
dialysis.(19)
Sample and Population
This study was approved by Hasanuddin University 
Ethical Committee with register number UH14110582 and 
was involving 75 chronic ischemic stroke patients (with 
stroke onset ≥30 days) in Cerebrovascular Center Gatot 
Soebroto Indonesian Army Central Hospital, started from 
February 2015 until September 2015. Subjects participated 
voluntarily and signed the informed consent. Subjects 
were assessed for their age, sex, stroke onset, hemiparesis 
side, lesion area, infarct size (lacunar if lesion <15 mm or 
non lacunar if ≥15 mm) and stroke risk factors, including 
dyslipidemia (total cholesterol >200 mg/dL, triglycerides 
>160 mg/dL, LDL >100 mg/dL and/or HDL <35 mg/dL), 
hypertension (blood pressure >140/90 mmHg), diabetes 
mellitus (fasting blood glucose >126 mg/dL or post prandial 
glucose >200 mg/dl or below with glucose lowering agents), 
hyperuricemia (uric acid >7 mg/dL), hypercoagulation 
(prothrombin time >11.8 seconds, APTT >47 seconds, 
fibrinogen >350 mg/ dL and D-dimer >400 ng/mL). Heart 
disease assessed by cardiologist after clinical examination 
and electrocardiography examination.
CBF Measurement
CBF was measured before and 4 hours after the IAHF 
therapy using sequence of MRI ASL Special work packages 
ASP “Addin Special Sequence Package”: N4_818_VD13A_
PFEUJODJ_Adv3DASL with single time inversion and 
protocol as below: field of view (FOV) 256x256 mm; slice 
thickness 5 mm; matrix size 64x64 pixel; repetition time 
(TR) 4000 ms; time to echo (TE) 18 ms; bandwidth 2.365 
Hz/pixel; coil head matrix; flip angle 180 degree; bolus 
duration 700 ms; time inversion 1990 ms; window width 
200; window center 100. CBF map is produced with Buxton 
parameter model. Region of interest was drawn around 
lesion using Syngovia post processing packages. CBF 
measurement unit is mL/100 g/min.
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Seventy five chronic ischemic stroke patients participated in 
our study. Subjects’ characteristics can be found in Table 1. 
CBF value was obtained with magnetic resonance imaging 
(MRI) quality arterial spin labeling (qASL) after post 
processing (Figure 1). Region of interest was placed among 
infarct lesion in three slices on every patient and the value 
was recorded. The average of pre-treatment CBF value 
was 25.22±13.09 mL/100g/min 35.61±18.63 mL/100g/min 
after IAHF treatment. The difference between post and pre-
treatment was 10.39 mL/100g/min or 41.20% improvement. 
Wilcoxon test was performed to analyze the differences. A 
significant differences CBF value was found before and 
after IAHF treatment (p<0.001)  (Table 2). 
 After the subgroup was classified based on age, sex, 
stroke onset, infarct size and lesion area, we analyze it 
statistically. Wilcoxon alternative test showed significant 
difference between pre- and post-test CBF in both male 
Results
Table 1. Subjects characteristic.
(24.18±11.98 mL/100g/min and 33.83±17.25 mL/100g/
min; p<0.001) and female subjects (28.77±16.28 mL/100g/ 
min and 41.68±22.24 mL/100g/min; p<0.001). In grouping 
based on age, significant difference was shown in subgroup 
subjects with age 41-60 years old (22.81±11.07 mL/100g/
min and 31.73±14.68 mL/100g/min; p<0.001) and subgroup 
>60 years old (30.27±15.94 mL/100g/min and 43.12±20.75 
mL/100g/min; p<0.001). But there was not found significant 
difference in subgroup subjects with age 18-40 years old 
(33.58±17.32 mL/100g/min and 52.74±43.15 mL/100g/
min; p>0.05)  (Table 3). 
 Significant difference was also found in all subgroup 
of stroke onset, subgroup with onset <1 year (29.26±13.82 
Variables Number of subjects (percentage)
Sex
Male 58 (77.33%)
Female 17 (22.67%)
Age
<40 years old 3 (4%)
41-60 years old 52 (69.33%)
>60 years old 20 (26.67%)
 Onset
<1 year 44 (58.67%
1-3 years 26 (34.67%)
>3 years 5 (6.67%)
Hemiparesis
Right 38 (50.67%)
Left 37 (49.33%)
Lesion size
Lacunar 48 (64%)
Non Lacunar 27 (36%)
Lesion Area
Cortex 11 (14.67%)
Subcortex 57 (76%)
Cortex-Subcortex 7 (9.34%)
Risk Factor
Dislipidemia 60  (80%)
Hypertension 52 (69.33%)
Diabetes Mellitus 24 (32%)
Hyperuricemia 17(22.67%)
Hypercoagulation 12 (16%)
Heart Disease 16 (21.33%)
IAHF-modified DSA Procedure
Initially, 5000 IU heparin was diluted with 500 mL Normal 
Saline Otsu (Otsuka, Lawang, Indonesia). Topical eutectic 
mixture of local anesthetics (EMLA) was applied on 
femoral artery area, continued with povidone iodine 7.5% 
and alcohol 70%. Local anesthetic, a lidocain, was injected 
intra cutaneously and subcutaneously. Femoral artery was 
punctured with abocath 18 G, and short guide wire was 
inserted. Fluoroscopy was performed to see the anatomical 
imaging. Diluted heparin was flushed intra arterial in both 
right and left carotid arteries and vertebral arteries. After 
completing the flushing process, femoral artery bleeding 
was stopped using either conventional technique with 
pressure given to puncture site using sandbag for 8 hours 
or angio seal.
Statistical Analysis
Statistical analysis was performed with SPSS 15.0. 
Kolmogorov-Smirnoff test was performed to find the data 
distribution model. The differences before and after IAHF 
treatment were tested using paired T-test or Wilcoxon 
test alternatively with p value of 0.05 were considered 
significant. The difference before and after IAHF treatment 
in subgroup classified with age, sex, stroke onset, infarct 
size, and lesion area were also tested using paired T-testor 
Wilcoxon test alternatively with p value of 0.05 were 
considered significant.
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Heparin was used for thrombosis treatment for a long 
time. DSA followed by IAHF treatment performed in 
chronic ischemic stroke patients in our study showed 
a significant improvement in CBF value, about 10.39 
mL/100g/min around the infarct area (p<0.001) in IAHF 
treated group. Rather than restoring the CBF into normal 
value, this improvement happened due to partial restoring 
of microcirculation. In this study, the CBF value increased 
after 4 hours of IAHF treatment. CBF changes (ΔCBF) can 
also reflecting vasodilatation or metabolic changes (20) 
and not always reflecting increase of micro vessel density 
so that was not have a high sensitivity as a angiogenesis 
marker (21). Increasing CBF here was not associated with 
angiogenesis because process sufficient time is needed to 
form angiogenesis. Slevin described that the new blood 
vessels formation were initiated through vascular buds, 
forming a connection with intact micro vessels after weeks 
post-ischemia.(22)
 Therapy strategy to reduce microvascular obstruction 
can increase oxygen flow to the tissue where entrapping 
red blood cells could not be circulated in capillaries. Serum 
reflow can increase cell survival after ischemia. Recent 
studies showed that CBF improvement support glial and 
neuronal cells recovery and related to neuronal activities 
but limited to ischemic cells without irreversible damage 
as known as penumbra.(5,23) Functional reorganization 
supported  by  survived  cells  around  infarct  core  or 
penumbra is an important mechanism in motor recovery 
after stroke.(24)
 CBF improved in all stroke onset subgroup, even in 
subjects with stroke onset more than 3 years. In subject with 
stroke onset started 6 years ago, less ΔCBF were obtained 
compare to other subjects. This showed that although 
IAHF could improve CBF in all chronic stroke subjects in 
this study, the sooner IAHF performed is the better. CBF 
improved in both female and male subjects suggested that 
sex give no differences in CBF improvement. In 3 subjects 
in the subgroup age 18-40 years old, CBF improvement 
was high (19.16±26.03 mL/100g/min) but not statistically 
significant (p>0.05). We found increasing CBF in both 
lacunar and non lacunar infarct, with the higher increasing 
CBF is in subjects with lacunar stroke. We also found CBF 
increasing in patients with cortical, subcortical and both 
cortical-subcortical lesion. Lower increasing CBF was 
Figure 1. Post processing qASL using Syngovia. CBF pre- 
treatment in region of interest (upper right) (devided with 10) 
23.45 mL/100g/min compared with post treatment (lower right) 
34.01 mL/100g/min in the same region using autoallignment.
mL/100g/min and 41.13±18.13 mL/100g/min; p<0.001), 1-3 
years (17.83±8.89 mL/100g/min and 25.77±16.44 mL/100g/ 
min; p<0.001) and >3 years (28.17±9.13 mL/100g/min and 
38.20±15.05 mL/100g/min; p<0.05) (Table 3). 
 Wilcoxon alternative test showed significant difference 
between pre- and post-test CBF in subjects with stroke 
ischemic in cortical lesion (22.29±12.71 mL/100g/min and 
32.83±16.83 mL/100g/min; p<0.05), subcortical lesion 
(26.60±13.47 mL/100g/min and 37.34±19.38 mL/100g/min; 
p<0.001) and both cortical-subcortical lesion (18.62±8.28 
mL/100g/min and 25.93±12.35mL/100g/min; p<0.05) 
(Table 3). CBF average increased as much as 10.54±8.61 
mL/100g/min in cortical lesion, 10.74±10.48 mL/100g/ 
min in subcortical lesion and 7.31±6.511 mL/100g/min in 
cortical-subcortical lesion (Figure 2).
 Wilcoxon alternative test showed significant 
difference between pre- and post-test CBF in subjects with 
stroke ischemic in lacunar infarct (28.26±13.72 mL/100g/ 
min and 39.83±19.87 mL/100g/min; p<0.001) and non 
lacunar infarct (19.81±10.01 mL/100g/min and 28.09±13.50 
mL/100g/min; p<0,001) (Table 3). CBF average increased 
as much as 11.57±11.06 mL/100g/min in lacunar infarction 
and 8.28±7.05 mL/100g/min in non lacunar or wide 
infarction (Figure 3).
Discussion
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Table 3. Correlation analysis between spirometric paramaters and the risk factors.
CBF value
(mL/100g/min) Mean±SD Median Mean p
Pre-treatment 25.22±13.09 23.81 5.79-78.29
Post-treatment 35.61±18.63 32.66 6.33-109.72
<0.001
Table 2. CBF differences before and after IAHF treatment.
Mean±SD Median   (Min-Max) Mean±SD
Median   
(Min-Max)
Sex
Male 24.18±11.98 24.01
(5.79-55.04)
33.83±17.25 32.50           
(6.33-102.30)
9.65±9.79 <0.001
Female 28.77±16.28 23.36       
(8.78-78.29)
41.68±22.24 36.43
(9.67-109.72)
12.91±10.06 <0.001
Age
18-40 years old 33.58±17.32 27.64        
(20.01-53.09)
52.74±43.15 32.37     
(23.55-102.30)
19.16±26.03 0.109
41-60 years old 22.81±11.07 22.15         
(6.24-55.04)
31.73±14.68 30.84
(9.32-80.05)
8.92±7.94 <0.001
>60 years old 30.27±15.94 26.62
(5.79-78.29)
43.12±20.75 43.22
(6.33-109.72)
12.89±10.74 <0.001
Stroke Onset
<1 year 29.26±13.82 25.69
(7.04-78.29)
41.13±18.13 38.06
(15.89-109.72)
11.87±9.88 <0.001
1-3 years 17.83±8.89 15.73
(5.79-37.73)
25.77±16.44 23.93
(6.33-80.05)
7.94±10.21 <0.001
>3 years 28.17±9.13 27.64
(18.63-42.42)
38.20±15.05 32.98
(21.60-61.69)
10.03±6.51 0.043 
Lesion Area
Cortex 22.29±12.71 18.37 
(6.24-47.86)
32.83±16.83 27.04
 (9.83-59.57)
10.54±8.61 0.003
Subcortex 26.60±13.47 25.32
 (5.79-78.29)
37.34±19.38 33.82 
(6.33-109.72)
10.74±10.48 <0.001
Cortex-Subcortex 18.62±8.28 21.65
 (7.36-29.77)
25.93±12.35 32.49 
(0.92-41.58)
7.31±6.51 0.018
Infarct Size
Lacunar 28.26±13.72 26.01
(7.04-78.29)
39.83±19.87 34.79
(9.67-109.72)
11.57±11.06 <0.001
Non-lacunar 19.81±10.01 19.75
(5.79-47.94)
28.09±13.50 27.04
(6.33-53.60)
8.28±7.05 <0.001
CBF Value
Post-Test
pΔCBF
Pre-Test
obtained if infarct area was wide or involved both cortical 
subcortical areas so that involving more blood vessel 
obstruction and wider core infarct lesion with irreversible 
damage. Our finding showed that IAHF has the potential 
to restore both macro and microcirculation by clot lytic 
and facilitate vasodilatation supported with its ability as 
anantioxidant.
 Heparin, an anticoagulant containing a number of 
additional effects such as anti-inflammatory andantioxidant, 
is a fundamental substance used during hemodialysis 
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sessions.(19) Heparin is glycosaminoglycan compound 
with highest negative charge density compare to any other 
molecules. Heparin affects free radical activity by modulating 
environment around the free radical. Heparin inhibits iron 
that catalyzing free radical peroxidation fromlinoleic acid. 
Heparin inhibits diene and thiobarbituric acid conjugation 
from reaction involving linoleic acid andiron. Heparin 
boosts the antioxidant effect of superoxidedismutase by 
releasing it near the endothelial cells of the vessels. On the 
Δ
C
B
F
Δ
C
B
F
Figure 2. CBF changes in lesion area subgroup. Subjects 
with lesion in subcortex has the highest changes with average 
10.74±10,48 mL/100g/min, followed by cortex (10.54±8.61 
mL/100g/min), and cortex-subcortex (7.31±6.51 mL/100g/min).
Figure 3. CBF changes in infarct size subgroup. Patients with 
lacunar infarct has higher changes with average 11.57±11.06 
ml/100gr/min, followed by non lacunar infarct 8.28±7.05 
ml/100gr/min.
other hand, heparin, as a sink of free radicals of oxygen 
in addition to iron and copper, the well known oxidants in 
inflamed tissues, plays properly its antioxidant role.(25) 
After ischemic, tissue level of acidity is lower than normal 
due to lactate accumulation. This variation alters antioxidant 
activity but heparin is known to have good activity even in 
low acidity environment.(19,26).
 Heparin with anti-inflammatory and antioxidant 
properties is capable to suppress oxidative stress.(19) Thus 
antioxidant properties prevent pericytes constriction, restore 
capillary patency and increase tissuerecovery.(12)
 Study by Nawashiro, et al., in effort to achieve CBF 
improvement performed by transcranial light-emitting 
diode (LED) in acute stroke patients, showed 20% increase 
in CBF leads to patients outcome improvement, tested by 
hand movement to reach things close to them. However, 
this therapy needs 73 days long with 146 treatments 
series to reach the desirable effect.(27) Earlier studies 
showed that vasodilator agents (acetazolamide, nylidrine, 
xylandelate, hydergine, papaverine) significantly increase 
CBF in acutestroke patients.(28) Statin is also used in some 
studiesas an alternative drug to increase CBF. Mechanical 
recanalization with endovascular stent on vascular stenosis 
showed CBFincreases as much as 21%±10%.(29)
 Sustainable physical therapies are still becoming a 
major strategy to obtain CBF improvement in chronic stroke 
patients. Study by Perrey, et al., using transcranial Doppler 
(TCD) reported that aerobic exercise supportsincrease 
in CBF increasing both global and regional.(20) They 
attributed task-induced vasodilatation to an increased 
demand for cerebral metabolism in response to neuronal 
activity, and found that during physical activities, CBF 
increases to supply adequate oxygen into the brain, and the 
CBF regulation seems to be crucial for the maintenance of 
cardiovascular homeostasis.(20,30)
 IAHF potency for vessel recanalization was not 
observed in this study. Substantial experimental data 
andrecent clinical evidences suggested that tissue reperfusion 
is a better predictor for after-thrombolysis outcome compare 
to recanalization. IAHF treatment in this studies showed 
a significant increased of CBF (41.20%), higher than any 
other CBF increasing strategies. Dalkara reported that 
therapeutic approaches aiming to reduce microvascular 
obstructions may improve the success rate of recanalization 
therapies. Substantially, by promoting oxygen delivery to 
the tissue, where entrapped erythrocytes cannot circulatein 
capillaries, marching with serum flow may improve survival 
of the under perfused tissue. These heaps upon the exciting 
 Alternative Therapy for Chronic Ischemic Stroke (Putranto TA, et al.)Indones  Biomed J. 2016; 8(2): 119-26DOI: 10.18585/inabj.v8i2.204
 125
We found that IAHF treatment can significantly improve 
CBF value in chronic ischemic stroke patients. This study 
gives a new hope that reperfusion therapy with IAHF can 
give benefit to increase microcirculatory function to support 
penumbral recovery with a wider window therapy.
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